Skip to main content

Siri Lillegraven

Seniorforsker | Nestleder REMEDY

Utdanning

  • Cand.med., Universitet i Oslo (profesjonsstudiet i medisin)
  • Master of Public Health, Harvard School of Public Health
  • Doktorgrad ved Institutt for klinisk medisin, Universitetet i Oslo

Stilling

  • Nestleder, Forskningssenter for behandling innen revmatologi og muskelskjelettsykdommer (REMEDY), Diakonhjemmet sykehus
  • Leder for Enhet for klinisk forskning, Diakonhjemmet sykehus
  • Førsteamanuensis, Institutt for helse og samfunn, Universitetet i Oslo

Interessefelt

  • Kliniske studier innen ortopedi og revmatologi med spesielt fokus på randomisert-kontrollerte studier

Annet

  • Leder av arbeidspakke 1 i REMEDY (Behandlingsstudier)
  • Mottaker av Marie Spångberg-prisen 2022

E-post

Denne e-postadressen er beskyttet mot programmer som samler e-postadresser. Du må aktivere javaskript for å kunne se den.

Telefon

Besøksadresse

Diakonhjemmet sykehus
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo

Postadresse

Diakohjemmet sykehus
Postboks 23 Vinderen
0319 Oslo

Prosjekter

WP1 - Behandlingsstudier

ARCTIC

Remisjon hos pasienter med revmatoid artritt: en randomisert kontrollert studie som undersøker bruk av ultralyd i klinisk oppfølging

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP1 - Behandlingsstudier

ARCTIC FORWARD

10-års oppfølging av pasienter med revmatoid artritt som mottok strukturert behandling-til-mål-terapi i tidlig sykdomsfase.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP1 - Behandlingsstudier

ARCTIC REWIND

Studie på nedtrapping av behandling ved revmatoid artritt uten tap av sykdomskontroll.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP1 - Behandlingsstudier

ARCTIC REWIND extension study

Langtidsoppfølging av pasienter med velkontrollert revmatoid artritt - ARCTIC REWIND forlengelsesstudien

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP1 - Behandlingsstudier

HIFSAT

Studie av kirurgisk tilnærming ved hoftebrudd

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP1 - Behandlingsstudier

MethMax

Maksimalisering av behandlingseffekt

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP1 - Behandlingsstudier

NOR-CACTUS

Sammenlikning av behandlingsstrategier ved karpaltunnelsyndrom

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP5 - Strategier for digital oppfølging

NOR-Flare

Avstandsoppfølging av pasienter med revmatoid artritt

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP1 - Behandlingsstudier

NOR-Sprint

Oppfølging av nydiagnostiserte pasienter med psoriasisartritt med og uten bildediagnostikk

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP5 - Strategier for digital oppfølging

OA-AID

Digitale mestringsverktøy og digital oppfølging for pasienter med kneartrose

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP1 - Behandlingsstudier

SQUEEZE

Maksimering av effekten av reseptbelagte legemidler ved revmatoid artritt 

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Publikasjoner

Publikasjoner hentet fra Nasjonalt vitenarkiv (NVA):

Development of Machine Learning Models for Predicting Non-Remission in Early RA Highlights the Robust Predictive Importance of the RAID Score-Evidence from the ARCTIC Study

2025

Longitudinal risk of serious infections in patients with inflammatory arthritis on immunomodulating therapy compared to controls

2025

Predictors of 1-year mortality in a clinical cohort of hip fracture patients

2025

Short-Term Clinical and Radiological Results of the Infinity Ankle Arthroplasty: A Prospective Study

2025

Remote monitoring or patient-initiated care in axial spondyloarthritis: a 3-armed randomised controlled noninferiority trial

2025

Recognition of Glycine Versus Nonglycine Citrulline Motifs Dictating the HLA Class II Association of Anticitrullinated Protein Antibodies: Insights From Autoantibody Profiling of 6,900 Scandinavian Patients With Rheumatoid Arthritis

2025

Three-Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial

2025

Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial

2024

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity

2024

Use of direct-acting anticoagulants (DOACs) delays surgery and is associated with increased mortality in hip fracture patients

2024

Five-Year Results of the Salto XT Revision Ankle Arthroplasty

2024

Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials

2024

Follow-Up of Patients With Axial Spondyloarthritis in Specialist Health Care With Remote Monitoring and Self-Monitoring Compared With Regular Face-to-Face Follow-Up Visits (the ReMonit Study): Protocol for a Randomized, Controlled Open-Label Noninferiority Trial

2023

Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial

2023

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis and Excellent Disease Control

2023

Rheumatology congresses post COVID-19: we cannot regress

2023

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis

2022

All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study

2022

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study

2022

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment

2021

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study

2021

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial

2021

MicroRNA Expression Differences in Blood-Derived CD19+ B Cells of Methotrexate Treated Rheumatoid Arthritis Patients

2021

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-To-Target strategy

2021

Conventional versus ultrasound treat to target: No difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis

2020

Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-to-Target Strategies

2020

Rheumatoid Arthritis Patients, Both Newly Diagnosed and Methotrexate Treated, Show More DNA Methylation Differences in CD4+ Memory Than in CD4+ Naïve T Cells

2020

Trends in All-Cause and Cardiovascular Mortality in Patients With Incident Rheumatoid Arthritis: A 20-year Follow-Up Matched Case-Cohort Study

2019

Validity and responsiveness of combined inflammation and combined joint damage scores based on the OMERACT rheumatoid arthritis MRI scoring system (RAMRIS)

2019

Peptidylarginine deiminase 4 (PAD4) activity in early rheumatoid arthritis

2019

Subclinical treatment targets in rheumatology: Lessons from randomized clinical trials in rheumatoid arthritis

2019

Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis

2019

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial

2018

Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol

2018

The impact of ultrasound on the use and efficacy of intraarticular glucocorticoid injections in early rheumatoid arthritis: Secondary analyses from a randomized trial examining the benefit of ultrasound in a clinical tight control regimen

2018

The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy

2018

Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: Associations to future good radiographic and physical outcomes

2018

The OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging (MRI) Scoring System: Updated Recommendations by the OMERACT MRI in Arthritis Working Group

2017

Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis

2017

Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria

2017

Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial

2016

Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach

2016

Validation of the OMERACT magnetic resonance imaging joint space narrowing score for the wrist in a multireader longitudinal trial

2015

The OMERACT MRI in arthritis working group - Update on status and future research priorities

2015

Rheumatoid arthritis quality measures and radiographic progression

2014

Update on the OMERACT Magnetic Resonance Imaging Task Force: Research and Future Directions

2014

Iterative development and reliability of the OMERACT Hand Osteoarthritis MRI Scoring System

2014

The OMERACT-RAMRIS Rheumatoid Arthritis Magnetic Resonance Imaging Joint Space Narrowing Score: Intrareader and Interreader Reliability and Agreement with Computed Tomography and Conventional Radiography

2013

Performance of Matrix-Based Risk Models for Rapid Radiographic Progression in a Cohort of Patients With Established Rheumatoid Arthritis

2013

What is the clinical relevance of erosions and joint space narrowing in RA?

2012

Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort

2012

Should modern imaging be part of remission criteria in rheumatoid arthritis?

2012

Update on Research and Future Directions of the OMERACT MRI Inflammatory Arthritis Group

2011

Development and Preliminary Validation of a Magnetic Resonance Imaging Joint Space Narrowing Score for Use in Rheumatoid Arthritis: Potential Adjunct to the OMERACT RA MRI Scoring System

2011

The OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) Is Reliable and Sensitive to Change: Results from an OMERACT Workshop

2011

Hand osteoarthritis and MRI: development and first validation step of the proposed Oslo Hand Osteoarthritis MRI score

2011

Comparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis

2010